Based on nearly any metric, the quarter was horrendous. Aphria struggled to bring new production online, experienced rising corporate and packaging costs, and took a $50 million write-down on its newly acquired Latin America assets.
As we head into the fourth quarter, here are three important trends to monitor.
Demand for cannabis worldwide continues to explode. By 2030, Canadian demand could reach $10 billion annually while the U.S. could surpass $40 billion. To meet this heavy growth, cannabis growers are scrambling to ramp production quickly.
Aphria’s management team has revealed its plans to eventually reach $1 billion in annual sales, but recent quarters have thrown that lofty goal into doubt. In fact, the company now anticipates flat revenue growth for the fourth quarter. What happened?
It turns out that scaling commercial-grade facilities in under 12 months is extraordinarily difficult. We’ve seen other disrupters like Elon Musk attempt similar feats and fail.
If Aphria can’t ramp its production this year, it will be leaving millions of dollars on the table. While new production facilities won’t come online until the second half of 2019, pay close attention to the details when management updates its anticipated production growth.
While scaling production can be difficult, doing it in a cost-efficient manner is even more troublesome.
Last quarter, Aphria’s corporate costs went up across the board. Not only did it need to expand its employee count, but Aphria also failed to automate most of its production as promised.
Incredibly, most of its packaging is still done by hand. If it can’t figure out how to automate this core process, Aphria will struggle to bring down costs alongside its competitors.
In April, company executives specifically highlighted their new focus on “automation and the development of new growing facilities,” but declined to give an exact date by which investors should expect these upgrades, instead noting that they are “mid-term” priorities.
Aphria’s management team keeps pushing its cost-cutting efforts into the future, but if it wants to win back the trust of investors, it needs to provide a solid plan for boosting margins.
Short sellers, investors who bet that a stock will fall in value, can wreak havoc in an instant. While many investors choose to ignore short sellers, pegging them as opportunists, it’s critical that you hear and judge their arguments for yourself.
Earlier this year, Quintessential Capital released a report evaluating Aphria’s stock following months of research, including visits to the company’s facilities in Jamaica, Argentina, and Colombia. The conclusion was dire.
Quintessential Capital charged Aphria insiders with creating and buying shell companies, changing their names and then selling them to Aphria at artificially-inflated prices.
The fact that Aphria has already taken a multi-million dollar write-down on its Latin America acquisition adds considerable credence to these allegations.
If Quintessential Capital is correct, there could be at least $200 million in additional write-offs to come.
You can bet that Quintessential Capital will be looking to push more damning information about Aphria public over the next few months. You’ll want to pay attention to anything else they reveal.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.
Fool contributor Ryan Vanzo has no position in any stocks mentioned.